Planned Interim Analysis of the GMMG-Concept Trial in High-Risk NDMM
Alexander Lesokhin, MD, presents data from an interim analysis of the GMMG-CONCEPT trial investigating an isatuximab-based quadruplet regimen for high-risk NDMM.
EP: 1.GRIFFIN Trial in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Final Subgroup Analysis
EP: 2.Treatment Approaches in Transplant-Eligible NDMM
EP: 3.Upfront Stem Cell Transplant and Maintenance Therapy in Transplant-Eligible NDMM
EP: 4.Analysis of Patients with Transplant-Eligible NDMM with High-Risk Cytogenetic Abnormalities who Received Frontline Daratumumab-Based Quadruplet Therapy
EP: 5.Treatment Approaches in High-Risk Transplant-Eligible NDMM Based on MRD Negativity
EP: 6.Planned Interim Analysis of the GMMG-Concept Trial in High-Risk NDMM
EP: 7.Comparing Quadruplet Combination Treatment Regimens in NDMM
EP: 8.Updated Analysis of the Phase 3 MAIA Study in Transplant-Ineligible Patients with NDMM
EP: 9.Clinical Assessment of Key Subgroups of the Phase 3 Maia Study in Transplant-Ineligible Patients with NDMM
EP: 10.IFM2020-05/Benefit: Isatuximab Plus Lenalidomide, Dexamethasone, and Bortezomib for Elderly Patients with Transplant-Ineligible NDMM
FDA Approves Cilta-Cel for Relapsed/Refractory Myeloma After 1 Therapy
April 6th 2024The FDA has approved ciltacabtagene autoleucel for the treatment of adult patients with relapsed/refractory multiple myeloma who have received at least 1 prior line of treatment, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.
Relapsed/Refractory Multiple Myeloma Trial Updates From ASCO 2023
August 7th 2023Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.
